TNFRSF8 and lymphoma: In this study, we compared 161Tb radioimmunotherapy targeting CD30—a receptor overexpressed in lymphomas—with 177Lu-radiolabeled therapy to evaluate the effect of 161Tb’s additional emission of conversion and Auger electrons.